WO2025022178 - IN-SITU MRNA VACCINE PRODUCTION METHOD AND DEVICE
National phase entry is expected:
Publication Number
WO/2025/022178
Publication Date
30.01.2025
International Application No.
PCT/IB2024/000418
International Filing Date
24.07.2024
Title **
[English]
IN-SITU MRNA VACCINE PRODUCTION METHOD AND DEVICE
[French]
PROCÉDÉ ET DISPOSITIF DE PRODUCTION DE VACCIN À ARNM IN SITU
Applicants **
APTE, Zachary, Schulz
Inventors
APTE, Zachary, Schulz
Priority Data
63/528,429
24.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3528 | |
| EPO | Filing, Examination, Granting | 33829 | |
| Japan | Filing, Examination, Granting | 3760 | |
| South Korea | Filing, Examination, Granting | 5341 | |
| USA | Filing, Examination, Granting | 14140 |
Total:
60,598
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to an in-situ device for producing nucleic acid-based vaccines and therapeutics, particularly RNA vaccines. The device integrates multiple steps of vaccine production, including DNA transcription into RNA, RNA purification, and RNA encapsulation in a lipid carrier, into a single automated unit. This approach reduces contamination risk and allows rapid, scalable production of vaccines, facilitating immediate responses to emerging infectious diseases and simplifying logistics by producing vaccines close to the point of care.[French]
La présente invention concerne un dispositif in situ permettant de produire des vaccins et des agents thérapeutiques à base d'acide nucléique, en particulier des vaccins à ARN. Le dispositif intègre de multiples étapes de production de vaccin, comprenant la transcription d'ADN en ARN, la purification d'ARN et l'encapsulation d'ARN dans un vecteur lipidique, en une seule unité automatisée. Cette approche réduit le risque de contamination et permet une production rapide et évolutive de vaccins, facilitant des réponses immédiates à des maladies infectieuses émergentes et simplifiant la logistique par production des vaccins proches du point d'intervention.